XDx's AlloMap Gets Positive Determination from Aetna | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Aetna has determined that the firm's AlloMap test is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.